CA3228815A1 - Nkp46-binding polypeptides and uses thereof - Google Patents

Nkp46-binding polypeptides and uses thereof Download PDF

Info

Publication number
CA3228815A1
CA3228815A1 CA3228815A CA3228815A CA3228815A1 CA 3228815 A1 CA3228815 A1 CA 3228815A1 CA 3228815 A CA3228815 A CA 3228815A CA 3228815 A CA3228815 A CA 3228815A CA 3228815 A1 CA3228815 A1 CA 3228815A1
Authority
CA
Canada
Prior art keywords
polypeptide
cancer
nkp46
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3228815A
Other languages
English (en)
French (fr)
Inventor
John C. Timmer
Brendan P. Eckelman
Rajay A. PANDIT
William Crago
Florian SULZMAIER
Heather KINKEAD
Nadja KERN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aatd Inc
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of CA3228815A1 publication Critical patent/CA3228815A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3228815A 2021-08-30 2022-08-29 Nkp46-binding polypeptides and uses thereof Pending CA3228815A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163238429P 2021-08-30 2021-08-30
US63/238,429 2021-08-30
PCT/US2022/075581 WO2023034740A1 (en) 2021-08-30 2022-08-29 Nkp46-binding polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
CA3228815A1 true CA3228815A1 (en) 2023-03-09

Family

ID=84047735

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3228815A Pending CA3228815A1 (en) 2021-08-30 2022-08-29 Nkp46-binding polypeptides and uses thereof

Country Status (7)

Country Link
US (1) US20250136681A1 (https=)
EP (1) EP4395895A1 (https=)
JP (1) JP2024534838A (https=)
CN (1) CN117940454A (https=)
CA (1) CA3228815A1 (https=)
TW (1) TW202319397A (https=)
WO (1) WO2023034740A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024206329A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
CN120025440A (zh) * 2023-11-21 2025-05-23 南京融捷康生物科技有限公司 一种抗Nkp46的单域抗体及其用途
WO2025137555A1 (en) * 2023-12-20 2025-06-26 Omniab, Inc. Polypeptides that bind to nkp46
WO2025168114A1 (en) * 2024-02-09 2025-08-14 Shanghai Epimab Biotherapeutics Co., Ltd. Multifunctional nk cell engager
CN120574323A (zh) * 2024-02-29 2025-09-02 安升（上海）医药科技有限公司 一种抗NKp46的单域抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016207278A1 (en) * 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins
US20210024631A1 (en) * 2018-03-28 2021-01-28 Orionis Biosciences, Inc. Bi-functional proteins and construction thereof
KR20210113265A (ko) * 2019-01-07 2021-09-15 인히브릭스, 인크. 변형된 il-2 폴리펩타이드를 포함하는 폴리펩타이드 및 이의 용도

Also Published As

Publication number Publication date
JP2024534838A (ja) 2024-09-26
CN117940454A (zh) 2024-04-26
EP4395895A1 (en) 2024-07-10
US20250136681A1 (en) 2025-05-01
WO2023034740A1 (en) 2023-03-09
TW202319397A (zh) 2023-05-16

Similar Documents

Publication Publication Date Title
US11919963B2 (en) CD123-binding polypeptides and uses thereof
US12331126B2 (en) OX40-binding polypeptides and uses thereof
US20220089667A1 (en) Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
CA3228815A1 (en) Nkp46-binding polypeptides and uses thereof
US20250320295A1 (en) CD8-Binding Polypeptides and Uses Thereof
US20250011436A1 (en) CLEC12a Binding Polypeptides and Uses Thereof
JP2021508449A (ja) Ｃｈ３ドメイン中に挿入された特異的ｐｄ−ｌ１結合配列
US20240376198A1 (en) NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof
US20250066477A1 (en) Gamma Delta T-Cell-Binding Polypeptides and Uses Thereof
WO2023004305A1 (en) Cd8-targeted modified il-2 polypeptides and uses thereof
US20250109203A1 (en) Gamma Delta T-Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof
CN117980335A (zh) Cd8结合多肽及其用途

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240823

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240823

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240823

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20241030

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241030

R15 Change to inventor requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R15-R108 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECT INVENTOR REQUEST RECEIVED

Effective date: 20250204

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250218

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250822

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250905

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260202

R16 Change to inventor recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R16-R110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECT INVENTOR REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260401

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260401

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260401